Recent 8-K filings for ACXP
Highest-materiality recent filing
Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement
- Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.
- Company has 45 days (until May 9, 2025) to submit a Compliance Plan to Nasdaq.
-
Acurx raises ~$2.5M in registered direct offering plus up to $4.6M from warrants
Priced 825,085 shares (or pre-funded warrants) at $3.03/share for ~$2.5M gross proceeds.
-
Acurx launches ibezapolstat pilot trial in recurrent CDI; Phase 2 showed 96% cure, no recurrence
CEO, Executive Chairman, CFO take 10% base salary cut; director cash retainers also reduced 10%, effective April 1, 2026.
-
All six proposals passed at July 17 meeting; 74.38% of shares represented.
-
Acurx Pharma raises $2.67M via warrant exercise; issues new warrants for ~8.89M shares
Entered warrant inducement agreement; holder exercised ~4.45M existing warrants at reduced $0.60/share, gross proceeds $2.67M.
-
Acurx Q1 net loss narrows to $2.1M ($0.11/sh); cash $4.6M; EMA guidance for ibezapolstat Phase 3
Net loss $2.1M ($0.11 diluted EPS) vs $4.4M ($0.28) Q1 2024; R&D fell to $0.6M, G&A to $1.6M.
-
Acurx Pharmaceuticals secures up to $12M equity line from Lincoln Park Capital
Lincoln Park committed to purchase up to $12M in common stock over 24 months.
-
Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement
Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.
-
Acurx Pharma reports FY 2024 net loss $14.1M; cash $3.7M; EMA guidance for Phase 3
Net loss Q4 2024 $2.8M ($0.16/diluted share) vs $5.1M ($0.37) in Q4 2023; FY 2024 net loss $14.1M ($0.87) vs $14.6M ($1.15).
-
Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period
Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.
-
Acurx Pharmaceuticals prices $2.5M registered direct offering of 2.46M shares at $1.015
Gross proceeds ~$2.5M from 2,463,058 shares at $1.015/share in registered direct offering.
-
Acurx Q2 net loss $4.1M, cash $6.4M; FDA confirms Phase 3 readiness for ibezapolstat
Net loss of $4.1M ($0.26/diluted share) for Q2 2024 vs. $3.4M ($0.28) in Q2 2023.
-
Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan
Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.
-
Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate
Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).
-
Acurx reports Q3 net loss of $3.1M; ibezapolstat Phase 2 shows 96% cure rate, advancing to Phase 3
Net loss $3.1M ($0.24/diluted share) vs $3.5M ($0.32) in Q3 2022; cash $7.1M at Sept 30, 2023.
-
Acurx reports 96% clinical cure rate in Phase 2 trial of ibezapolstat for C. difficile infection
96% clinical cure rate (25/26 patients) in combined Phase 2a and 2b trials of ibezapolstat.
-
Phase 2b discontinued after blinded data showed high clinical cure rates for ibezapolstat and vancomycin, with no emerging safety concerns.
-
Acurx Pharma prices $4M registered direct offering of common stock and warrants
Gross proceeds of ~$4M from sale of 1,333,333 shares (or pre-funded warrants) at $3.00 per share.
-
Acurx reports Q4/FY2022 net loss; Phase 2b CDI trial interim IDMC review at 36 patients
Cash $9.1M at Dec 31, 2022 vs $13.0M a year earlier.
-
Acurx reports Q3 net loss of $3.5M; cash $10.6M; Phase 2b enrollment continues
Net loss of $3.5M ($0.32 per diluted share) for Q3 2022, vs $4.6M ($0.46) in Q3 2021.
-
Acurx reports Q2 2022 net loss of $2.6M; Phase 2b trial enrollment continues with site expansion
Net loss $2.6M ($0.26/diluted) for Q2 2022 vs $4.0M ($0.57) a year ago.
-
Acurx Q2 2021 net loss $4.0M ($0.57/diluted share); IPO raised $17.25M gross
Net loss of $4.0M for Q2 2021 vs $0.9M loss in Q2 2020; R&D expenses down to $0.1M from $0.4M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material